Application of thymic factor "Thymalin" in complex treatment of endometrial cancer patients.
Indications have been received of cell immunity in 111 primary endometrial cancer patients in the process of complex treatment: hormonotherapy+surgery. These indices have revealed correlation with pathogenetic variants of disease. Suppression has also been registered of T-lymphocytes under the influence of complex treatment. 35 patients received thymic factor "Thymalin" as a component of complex treatment. Its positive effects on cell immunity and some clinico-morphological parameters have been registered.
Bakhidze
E V
EV
Division of Gynecologic Oncology, N.N. Petra Research Institute of Oncology of the USSR Ministry of Health, Leningrad.
Bokhman JaV
D000077713:17 alpha-Hydroxyprogesterone Caproate; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology; D002478:Cells, Cultured / Q000187:drug effects; D003131:Combined Modality Therapy; D004958:Estradiol / Q000494:pharmacology; D005260:Female; D006801:Humans; D006908:Hydroxyprogesterones / Q000494:pharmacology; D007111:Immunity, Cellular / Q000187:drug effects / Q000502:physiology; D008875:Middle Aged; D012397:Rosette Formation; D015996:Survival Rate; D016176:T-Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology; D013629:Tamoxifen / Q000494:pharmacology; D013951:Thymus Hormones / Q000627:therapeutic use*; D014594:Uterine Neoplasms / Q000276:immunology / Q000401:mortality / Q000628:therapy*
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D006908:Hydroxyprogesterones; D013951:Thymus Hormones; D013629:Tamoxifen; D000077713:17 alpha-Hydroxyprogesterone Caproate; D004958:Estradiol; C032805:thymalin